All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol

Blood

Volumn 100, Issue 13, 2002, Pages 4298-4302

  Tallman, Martin S ^a,b   Andersen, Janet W ^c   Schiffer, Charles A ^d,e   Appelbaum, Frederick R ^f,g   Feusner, James H ^h   Woods, William G ⁱ   Ogden, Angela ^j,k   Weinstein, Howard ^l   Shepherd, Lois ^m   Willman, Cheryl ⁿ   Bloomfield, Clara D ^o   Rowe, Jacob M ^p   Wiernik, Peter H ^q  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Eastern Cooperative Oncology Group ECOG   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e Cancer and Leukemia Group B Central Office   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g Southwest Oncology Group   (United States)

^h CHILDREN S HOSPITAL OAKLAND   (United States)

ⁱ CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^j TEXAS CHILDREN S CANCER CENTER   (United States)

^k Pediatric Oncology Group   (United States)

^l HARVARD MEDICAL SCHOOL   (United States)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF NEW MEXICO   (United States)

^o OHIO STATE UNIVERSITY   (United States)

^p TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^q NEW YORK MEDICAL COLLEGE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; RETINOIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FACTORIAL ANALYSIS; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 0037115195     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0632     Document Type: Article

References (41)

1. Fenaux P, Castaigne S, Dombret H, et al. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases. Blood. 1992;80:2176-2181.
2. Ohno R, Yoshida H, Fukutani H, et al. Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia. 1993;7:1722-1728.
3. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood. 1995;85:1202-1206.
4. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML-RAR α-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 1997;90:1014-1021.
5. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. Blood. 1999;94:3015-3021.
6. Fenaux P, Le Deley MC, Castaigne S, et al. All-trans retinoic acid in newly diagnosed acute promyelocytic leukemia: Results of a multicenter randomized trial. Blood. 1993;82:3241-3249.
7. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoid acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
8. Burnett AK, Grimwade D, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Results of the randomized MRC trial. Blood. 1999;93:4131-4143.
9. Fenaux P, Chevret S, Guerci A, et al. Long-term follow-up confirms the benefits of all-trans retinoic acid in acute promyelocytic leukemia. Leukemia. 2000;14:1371-1377.
10. Fenaux P, Chastang G, Chevret S, et al. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94:1192-1200.
11. Gallagher RE, Willman C, Slack JL, et al. Association of PML-RAR a fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study. Blood. 1997;90:1656-1663.
12. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definition of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
13. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing for ordered categorical data. Biometrics. 1984;40:819-825.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. PETHEMA Group. Blood. 1999;94:3015-3021.
16. Head D, Kopecky K, Weick J, et al. Effect of aggressive daunorubicin therapy on survival in acute promyelocytic leukemia. Southwest Oncology Group. Blood. 1995;86:1717-1728.
17. Bernard J, Weil M, Boiron M, Jaquillat C, Flandrin G, Gemon ME. Acute promyelocytic leukemia: Results of treatment by daunorubicin. Blood. 1973;41:489-496.
18. Avvisati G, Mandelli F, Petti MC, et al. Idarubicin (4-demethoxy daunorubicin) as a single agent for remission induction of previously untreated acute promyelocytic leukemia: A pilot study of the Italian cooperative group GIMEMA. Eur J Haematol. 1990;44:257-260.
19. Paietta E, Andersen J, Racevskis J, et al. Significantly lower P-glycoprotein expression in acute promyetocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses. Leukemia. 1994;8:968-973.
20. Michieli M, Damiani D, Ermacora A, et al. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukemia. Br J Haematol. 2000;108:703-709.
21. Takeshita A, Shinjo K, Naito K, et al. Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukemia cells: Analysis of intracellular concentration of ATRA. Br J Haematol. 2000;108:90-92.
22. McKenna RW, Parkin J, Bloomfield CD, Sundberg RD, Brunning RD. Acute promyelocytic leukemia: A study of 39 cases with identification of a hyperbasophilic microgranular variant. Br J Haematol. 1982;50:201-214.
23. Davey FR, Davis RB, MacCallum JM, et al. Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol. 1989;30:221-227.
24. Ohno R, Asou N, Kanamaru A, et al. The JALSG APL92 study for newly diagnosed acute promyelocytic leukemia (APL): Analysis of prognostic factors to increase cure rate in the next study [abstract]. Blood. 1999;94:2262a.
25. Chou WC, Tang JL, Yao M, et al. Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: A high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment. Leukemia. 1997;11:921-928.
26. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol. 1998;16:78-85.
27. Sanz M, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96:1247-1253.
28. Baer MR, Stewart CC, Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: Implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001;97:3574-3580.
29. Iizuka Y, Aiso M, Oshimi K, et al. Myeloblastoma formation in acute myeloid leukemia. Leuk Res. 1992;18:885-887.
30. Ikushima S, Yoshihara T, Matsumura T, et al. Expression of CD56/NCAM or hematopoietic malignant cells. A useful marker for acute monocytic an megakaryocytic leukemias. Int J Hematol. 1991;54:395-403.
31. Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural crest adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21) (q22;q22). Blood. 1997;90:1643-1648.
32. Raspadori D, Damiani D, Lenoci M, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 2001;15:1161-1164.
33. Murray CK, Estey E, Paietta E, et al. CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome. J Clin Oncol. 1999;17:293-297.
34. Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2000;18:1295-1300.
35. Lo Coco F, Diverio D, Avrisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood. 1999;94:2225-2229.
36. Lo Coco F, Diverio D, Falini B, et al. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood. 1999;94:12-22.
37. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360.
38. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-1348.
39. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patient. Blood. 1999;94:3315-3324.
40. Huan S-Y, Yang CH, Chen Y-C. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: A useful salvage therapy. Leuk Lymphoma. 2000;38:283-293.
41. Soignet SL, Frankel SR, Dover D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860.